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IntroductIon
Idiopathic inflammatory myopathies (IIM) are systemic
autoimmune diseases characterized by symmetrical,
proximal muscle weakness. Inflammation of skeletal
muscles and internal organs underpin IIM, leading to
irreversible damage and even death. The Bohan and Pe-
ter criteria is widely used for the diagnosis of IIM1.
Myositis is a disease with varied manifestations, and
therefore an heterogeneous condition. With the help of
myositis-specific autoantibodies (MSAs) we can divide
patients, in most cases, into homogenous groups where
the symptoms, response to therapy and prognosis are
simi lar to each other. The MSAs are directed against
speci fic proteins found in the cytoplasm or in the nu-
cleus of the cells. It is proven2-4 that these autoantibo -
dies have strong associations with clinical features and
survival in adult and juvenile myositis patients (Table
I). Autoantibodies preferentially associated with lung
involvement are anti-Jo-1, anti-PL-7, anti-PL-12, anti-
-EJ, anti-OJ, anti-KS, anti-HA and anti-Zo (anti-ami -
no-acyl-tRNA synthetase (ARS) autoantibodies)5,6. 
Dermatomyositis (DM)-associated autoantibodies are
anti-Mi- 2 and the recently detected anti-MDA5, anti-
-TIF1γ, anti-NXP2 and anti-SAE7,8. Autoantibodies
found in patients with necrotizing autoimmune 
myopathy (NAM) are anti-SRP and the recently re -
cognized anti-200/1009-16. The autoantigen for anti-
-200/100 was recently identified as being 3-hydroxy-
-3-methylglutaryl-coenzyme A reductase (HMGCR)12.
Anti-Mup44 autoantibodies, which are targeted to 
cytosolic 5’nucleotidase 1A (cN1A), represent the 
first serolo gical biomarker for sIBM (sporadic inclu-
sion body myositis) and may facilitate the diagnosis 
of this type of myositis16. These autoantibodies distin-
guish IIM from acquired or genetic muscular disease.
Cases have demonstrated a correlation between au-
toantibody titer and disease activity, thus predicting
prognosis17.
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AbstrAct 
Idiopathic inflammatory myopathies are systemic,
chronic autoimmune diseases characterized by sym-
metrical, proximal muscle weakness. Homogeneous
groups present with similar symptoms. The response to
therapy and prognosis could be facilitated by myositis-
-specific autoantibodies, and in this way, give rise to
immunoserological classification. The myositis-speci fic
autoantibodies are directed against specific proteins
found in the cytoplasm or in the nucleus of the cells. To
date, literature suggests the rarity of the co-existence
of two myositis-specific autoantibodies. In this study
the authors highlight rare associations of myositis-spe-
cific autoantibodies. Three hundred and thirty-seven
Hungarian patients with polymyositis or dermato-
myositis were studied. Their clinical findings were no -
ted retrospectively. Specific blood tests identified six
patients with the rare co-existence of myositis-specific
autoantibodies, anti-Jo-1 and anti-SRP, anti-Jo-1 and
anti-Mi-2, anti-Mi-2 and anti-PL-12, anti-Mi-2 and
anti-SRP, and anti-SRP and anti-PL-7, respectively. This
case review aims to identify the clinical importance of
these rare associations and their place within the im-
munoserological classification.
Keywords:Anti-Mi-2; Anti-SRP; Idiopathic inflamma -
tory myopathy; Anti-synthetase syndrome.
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This study aims to highlight rare associations of
myositis-specific autoantibodies. Six Hungarian 
patients positive for double MSA have been studied.
Clini cally, these patients presented with muscle symp-
toms, skin lesions and extramuscular manifestations.
MEthods
PAtIEnts
The Department of Clinical Immunology in the Medi -
cal Faculty at the University of Debrecen oversees five
hundred and forty patients with IIM. The Myositis An-
tibody Research Project is coordinated together with
the Bath Institute for Rheumatic Diseases. We evalua -
ted the autoantibodies of 337 Hungarian patients
diagno sed with myositis admitted to the University of
Debrecen between 1990 and 201418. The diagnosis of
PM/DM was based on the Bohan and Peter criteria. We
retrospectively collected their clinical data using the
EuMyoNet database and patients’ descriptions. All pa-
tients were either current or former patients at the Uni-
versity of Debrecen. This study is ethically compliant
and was carried out in compliance with the Declara-
tion of Helsinki19. Informed consent was obtained from
all subjects.
AntIbody-dEtEctIon 
The Regional Immunological Laboratory in Debrecen
detected the following MSAs: anti-Jo-1, anti-PL-7, anti-
-Pl-12, anti-Mi-2 and anti-SRP. These antibodies were
detected by membrane-fixed immuno-blot (Orgentec
Diagnostika). The method is briefly described. First,
the contents of each vial of buffered wash solution con-
centrate were diluted with distilled water to a final
volu me of 1000 mL prior to use. A myositis plus strip
was inserted and 1 mL of sample buffer was added to
each chamber of the incubation tray. Then, it was equi-
librated for 5 min with gentle rocking. 10 μL of sera
was added to each chamber and incubated for 60 min
at room temperature. Then, the diluted serum was re-
moved from the strips. 2 mL of wash buffer was added;
it was incubated for 5 min and then removed. This
procedure had to be repeated twice. 1.0 mL of the en-
zyme conjugate was added to each chamber and in-
cubated for 30 min. After removing the diluted con-
jugate, 2.0 mL of wash buffer was added and it was in-
cubated for 5 min; then, it was removed and this step
was repeated a further two times. After adding 1 mL
of substrate to each strip, a 10 min incubation was per-
formed and, after removing the substrate, it was
washed with 1 mL of distilled water, three times20.
The recently discovered MSAs (anti-TIF1γ, anti-
-NXP2, anti-SAE and anti-MDA5) were detected in the
UK by radiolabelled protein immunoprecipitation
(IPP). Briefly, ten µl sera was mixed with 2 mg protein-
-A-Sepharose beads (Sigma, UK) in IPP buffer (10 mM
Tris-Cl pH 8.0, 500 mM NaCl, 0.1% v/v Igepal) at
room temperature for 30 min. Beads were washed in
IPP buffer prior to the addition of 120 µl [35S] me-
thionine labelled K562 cell extract. Samples were
mixed at 4°C for 2 hr. Beads were washed in IPP buffer
followed by TBS buffer (10 mM Tris-Cl pH 7.4, 150
mM NaCl) before being resuspended in 50 µl SDS
sample buffer (Sigma, UK). After heating, proteins
were fractionated by 10% SDS PAGE, enhanced, fixed
and dried. Labelled proteins were analysed by autora-
diography.
The antibody results for anti-Jo-1, anti-PL-7, anti-
-PL-12, anti-Mi-2 and anti-SRP were re-tested in Bath
by IPP and the results were similar. Similarity means
that nine anti-Jo-1 positive patients were only positive
in Debrecen, eight anti-Jo-1 patients only in Bath. The
cause of this difference was that some of the sera were
not collected at the same time. This result confirms
that the anti-Jo-1 positivity can disappear during di -
sease progress21. Our reported six patients’ results were
the same in Bath and in Hungary. Anti-TIF1γ, anti-
-NXP2, anti-SAE and anti-MDA5 were only tested in
Bath. Other anti-ARS autoantibodies (anti-EJ, anti-KS,
anti-OJ, anti-Zo) were also tested in Bath; none of the
patients were positive for these MSAs. Other MSAs
(anti-200/100 and anti-Mup44) were tested neither in
Hungary nor in the UK; this is one important limita-
tion of our study.
MAnuAL MuscLE tEstIng
The muscle strength of patients was defined by the
manual muscle testing (MMT) score. MMT of proximal
muscle groups has been used as a major end point for
IIM therapeutic trials. It has also been used in clini cal
practice to follow patients longitudinally. Traditional-
ly, MMT has been assessed using 5-point MMT scales,
including the Medical Research Council Scale22. An ex-
panded 0–10-point MMT scale23 has also been used in
recent therapeutic trials, which is postulated to be
more sensitive in delineating weakness. Routinely, we
also examined the following eight muscle groups on a
0–10 scale: neck flexors, musculus deltoideus, mus-
culus biceps brachii, musculus gluteus maximus, mus-
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PAtIEnts wIth two MsAs
ANTI-JO-1 AND ANTI-SRP POSITIVITY
Two female patients tested positive for anti-Jo-1 and
anti-SRP antibodies. The first patient, a seventy years
old female, presented with acute onset of proximal
muscle weakness without myalgia. Disability, fatigue
and lethargy subsequently followed. In three months
the patient lost sixteen kg weight. Laboratory testing
showed elevated creatine phosphokinase (CK) (5970
U/L; normal range 24-195 U/L; Figure 2) and lactate
dehydrogenase (LDH) (2860 U/L; normal range 135-
-220 U/L) and she had anti-Jo-1 positivity. Elec-
tromyography (EMG) showed typical myogen damage
with myogen potentials. The muscle biopsy (m. del-
toideus) showed a high variation of muscle fibre cali-
bre, endomysial inflammation with macrophages and
lymphocytes, and MHC-I upregulation. Necrosis was
not detected. The patient had severe dysphagia in addi -
tion to Raynaud’s phenomenon, mechanics hand,
kerato conjunctivitis sicca and osteoporosis. Medically,
methylprednisolone proved to be effective in the ma -
nagement of her symptoms. Regular physiotherapy im-
proved the patients muscle strength. The patient was
followed with high-resolution computed tomography
(HRCT). One year after disease onset the patient de-
veloped alveolitis and then pulmonary fibrosis. Cy-
clophosphamide therapy was prescribed to reduce fur-
ther deterioration of the lung function. Cyclophos-
culus gluteus medius, musculus quadriceps femoris,
wrist extensors and ankle dorsiflexors. All muscle
groups were assessed bilaterally, with the exception of
the muscles of the neck. This together gene rated a max-
imum MMT score of 150 or a maximum MMT score of
80 (unilaterally).
AssEssIng thE PhysIcAL FunctIon 
The health assessment questionnaire (HAQ) was used
to assess physical function. The HAQ disability index
is designed to assess patients’ usual abilities, disabilities
and discomfort; it is based on the past week24,25. Each
questionnaire is graded with a score between 0 and 3,
with three being the most unfavorable.
rEsuLts
IMMunosEroLogIcAL cLAssIFIcAtIon 
All three hundred and thirty-seven patients were Cau-
casian. The mean age of the patients was 54.8 years
(the oldest patient was 90 and the youngest patient was
9 years old); the women/men ratio was 2.9:1.
Among the three hundred and thirty-seven exami -
ned patients, there were one hundred and thirty-three
positive MSA patients (39.5% of all patients with IIM)
(Figure 1). Among the positive MSA patients sixty-two
(46.6% of all MSA) were positive for anti-Jo-1 antibo -
dies. In addition to the anti-Jo-1 antibody, two o ther
anti-ARS antibodies could be detected. One of which
was the anti-PL-7 autoantibody, with a total of four ca -
ses (3% of all MSA); and the anti-PL-12 autoantibody,
with one case (0.8% of all MSA). We had 67 patients
with anti-ARS positivity: 19.9% of all IIM patients and
50.4% of all MSA patients. Twenty-six patients, 19.6%
of all MSA positive patients yielded anti-Mi-2 cases
whilst fourteen cases, 10.5% of all MSA positive pa-
tients presented with anti-SRP positivity. We could de-
tect anti-TIF1-γ positivity in twelve patients (9% of all
MSA). Anti-SAE positivity was detected in four pa-
tients; anti-NXP-2 positivity was detected also in four
patients (3%-3% of all MSA). Anti-MDA5 was not de-
tected in any patients. Double MSA positivity was de-
tected in six cases. This means that six patients had 
two MSAs in their sera. Two patients were positive for
anti--Jo-1 and anti-SRP antibody (1.5% of all MSA).
The other four patients (3% of all MSA) presented with
anti--Jo-1 and anti-Mi-2; anti-Mi-2 and anti-SRP; anti-
-Mi-2 and anti-PL-12; and anti-SRP and anti-PL-7 an-
tibodies.
Distribution of MSA antibodiesAnti-Jo-I:
62 patients (46.6%)Anti-Mi-2:
26 patients (19.6%)Anti-SRP:
14 patients (10.5%)Anti-PL-7:
4 patients (3%)Anti-PL-12:
1 patients (0.8%)Anti-TIFIγ:
12 patients (9%)Anti-NXP2:
4 patients (3%)Anti-SAE:
4 patients (3%)Double MSA positivity:
6 patients (4.5%)
Distribution of MSA antibodies
Anti-Jo-I:
62 patients (46.6%)
Anti-Mi-2:
26 patients (19.6%)
Anti-SRP:
14 patients (10.5%)
Anti-PL-7:
4 patients (3%)
Anti-PL-12:
1 patients (0.8%)
Anti-TIFIγ:
12 patients (9%)
Anti-NXP2:
4 patients (3%)
Anti-SAE:
4 patients (3%)
Double MSA positivity:
6 patients (4.5%)
FIgurE 1. Immunserological classification of our Hungarian
patients with MSA positivity 
(Abbreviations: MSA: myositis-specific autoantibody; NXP2: nuclear
matrix protein 2; SAE: small ubiquitin-like modifier activating
enzyme; TIF1γ: transcriptional intermediary factor 1 gamma) 
ÓRGÃO OFICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
341
bodoki l et al
phamide therapy was repeated six times, and the pa-
tient was in a remissive state for several years. Five years
after the onset she was diagnosed with anti-SRP posi-
tivity. During her last examination she had severe mus-
cle weakness and myalgia (the MMT scores were 29/80
and 56/150), arthralgia, severe dysphagia and dys -
pnoea at exertion. Some months later – at the age of
eighty - she died due to heart failure.
Our second patient was diagnosed with DM at the
age of forty-nine: she had muscle weakness, arthralgia,
Raynaud’s phenomenon, shawl-sign and erythema on
face. Laboratory tests gave an extremely high CK (9210
U/L; Figure 2), in addition to the anti-Jo-1 and anti-
-SRP positivity. The muscle biopsy was positive for DM.
The inflammatory infiltration had perivascular and
peri mysial location, also macrophages and neutrophils
could be detected in the involved area. EMG changes
included myopathic motor unit potentials without
fibri llations. The result of HRCT at disease onset was
pulmonary fibrosis. Treatment with methylpredni -
solone and cyclophosphamide was commenced. In the
course of the year, skin involvement disappeared but
muscular involvement progressed and worsened.
Steroid therapy continued and a higher dose vastly im-
proved proximal muscle strength. At present, the pa-
tient is sixty and is in remission with arthralgia being
an intermittent presenting complaint.
ANTI-JO-1 AND ANTI-MI-2 POSITIVITY
The third patient with hypertension, obesity and carpal
tunnel syndrome presented with her first muscular
symptoms aged fifty. In this case, proximal muscle
weakness and myalgia were present. The laboratory
values showed elevated CK (at first measurement 7890
U/L; Figure 2), and LDH levels (at first measurement
1396 U/L). EMG showed fibrillation at rest, polypha-
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Patient 4 (anti-Mi-2 + anti-PL-12)
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FIgurE 2. CK level of the six examined Hungarian patients with double MSA positivity
(Abbreviations: CK: creatine phosphokinase; MSA: myositis-specific autoantibodies; SRP: signal recognition particle) 
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sic potentials of short duration and low amplitude,
spontaneous and positive sharp waves. The muscle
biopsy showed endomysial mononuclear cells (around
and between myofibres) and also myonecrosis. HRCT
showed alveolitis and lung fibrosis; the patient com-
plained about dyspnoea. The autoantibody detection
confirmed anti-Jo-1 and anti-Mi-2 positivity. Methyl-
prednisolone was prescribed initially which subse-
quently improved muscle strength. This however was
short lived, myalgia and loss of proximal muscle func-
tion progressed within six months. Upper limb was also
involved as IIM advanced. Azathioprine was greatly
beneficial and dissolved her symptoms. Now the pa-
tient is sixty-four years of age, in remission and free of
symptoms and immunosuppressive therapy. She has
neither skeletal, nor gastrointestinal, nor cardiovascu-
lar disease activity. She is regularly controlled with
HRCT; the lung fibrosis is only present at the basis of
the lung and she has no dyspnoea. The muscle disease
is also inactive: the MMT scores during the last four
exa minations were 77/80 and 143/150; 78/80 and
147/150; 78/80 and 147/150; 71/80 and 134/150; res -
pectively. Serum levels of muscle enzymes were wi thin
normal range.
ANTI-MI-2 AND ANTI-PL-12 POSITIVITY
The fourth patient had very severe myalgia and became
very weak at the age of sixty-eight. His disease was very
progressive DM. At disease onset he had stationary
fever (38°C or higher), heliotrope rash, erythema on
his face, shawl-sign, Raynaud’s phenomenon, dyspha-
gia and arthralgia. EMG showed myopathic pattern
with spontaneous activity and polyphasic potentials of
short duration. Interestingly, muscle biopsy showed a
very high variation of muscle fibre calibre and some
necrotic fibres. Some lymphocytes were present but the
typical mononuclear cell infiltration could not be de-
tected. Vacuolated muscle fibres were also present. He
had severe lung involvement: alveolitis and fibrosis –
according to the result of HRCT and DLCO test. CK
level was extremely high, 62550 U/L and this extreme
level lasted more than one month (Figure 2). Other
labo ratory parameters: LDH 5298 U/L, serum gluta -
mic oxaloacetic transaminase (SGOT) 1841 U/L (nor-
mal range <40 U/L), serum glutamic pyruvic transami -
nase (SGPT) 381 U/L (normal range <40 U/L). His
serum was anti-Mi-2 and anti-PL-12 positive. Accord-
ing to the biopsy findings IBM could also have been a
possible diagnosis; but it was excluded as the duration
of illness was not more than six months and distal mus-
cles were not affected. The patient was commenced on
a high dose of steroid. The patient’s symptoms pro-
gressed unfavorably and before his death due to aspi-
ration pneumonia at sixty-eight, he was bedridden.
ANTI-MI-2 AND ANTI-SRP POSITIVITY
Our next patient presented with myalgia at aged thir-
ty-seven. Myalgia was presented bilaterally in the mus-
culus quadriceps femoris. The patient was unable to
climb stairs and had proximal muscle weakness with
upper limb involvement. The patient did not have any
extramuscular involvement. CK level was 7320 U/L
(Figure 2), the LDH level was 21087 U/L. The CK-MB
level was also high (579 U/L), she had troponin-T posi -
tivity. Her serum was positive for anti-Mi-2 and anti-
-SRP antibodies. The characteristic triad of increased
insertional activity, spontaneous, bizarre high-fre-
quency discharges and polyphasic motor unit poten-
tials of low amplitude and short duration could be de-
tected with EMG. The muscle biopsy showed focal in-
vasion of muscle fibers by inflammatory cells and no
vacuoles. She got pulse methylprednisolone therapy.
She was treated with cyclosporine A, cyclophospha -
mide, methotrexate and finally with intravenous im-
munoglobulin. This was effective but the patient still re-
quires steroid and methotrexate therapy. She current-
ly shows signs of chronic myositis with generalized fa-
tigue and muscle weakness. Her MMT scores during
the last two examinations were 57/80 and 105/150;
55/80 and 94/150 respectively.
ANTI-SRP AND ANTI-PL-7 POSITIVITY
The female patient had her first symptoms at the age of
forty: myalgia, fatigue, proximal muscle weakness. CK
level and LDH level were not high, no antibody was
detectable, EMG was negative and muscle biopsy was
unremarkable. She was treated with steroid, in the next
three years she had only some weakness in her limbs.
Then, at the age of forty-three, she could not climb the
stairs because she had severe weakness and general fa-
tigue. Both EMG and muscle biopsy were conducted
and the diagnosis of PM was given. The muscle biops y
showed endomysial mononuclear cell infiltration, mus-
cle fibre calibre was normal and no vacuoles were visi -
ble. EMG showed fibrillation at rest and polyphasic po-
tentials of short duration and low amplitude. Her
serum was positive for anti-SRP and anti-PL-7 antibo -
dies. Interestingly, CK level remained at normal levels
(Figure 2). She got higher dose of methylprednisolone
and methotrexate. Now – with this therapy – she is in
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tAbLE II. MyosItIs-sPEcIFIc AutontIbodIEs And cLInIcAL AssocIAtIons2,5,10,16
Frequency 
Myositis-specific Frequency in in juvenile
autoantibodies Target autoantigen Clinical features adults (IIM%) patients (IIM%)
1. Anti-ARS Amino-acyl-tRNA synthetase ASS: 30-40% 1-3%
- myositis
- symmetrical non-erosiv arthritis
- Raynaud’s phenomenon
- ILD
- fever
- mechanic’s hand
Anti-Jo-1 Histidyl Classical ASS 15-20%
Anti-PL-7 Theronyl ILD before myositis <5%
Anti-PL-12 Alanyl ILD before myositis <5%
Anti-EJ Glycyl Chronic, therapy refracter ILD <5%
Anti-OJ Isoleucyl Chronic, therapy refracter ILD <5%
Anti-KS Asparaginyl <5%
Anti-HA Tyrosyl <1%
Anti-Zo Phenylalanyl <1%
2. Anti-Mi-2 Nucleosome remodeling DM: <10% 4-10%
deacetyalse complex (NuRD) - in general mild progress
3. Anti-SRP Signal recognition particle PM, NAM: 5% <3%
(SRP) - in general rapid progress
- severe myositis
- severe cardiac involvement
- severe dysphagia
4. Anti-SAE Small ubiquitin-like modifier DM: <5% <1%
activating enzyme (SAE) - severe skin lesions
- adults: dysphagia
5. Anti-TIF1γ Transcriptional intermediary DM: 13-21% 23-29%
factor 1 gamma (TIF1-γ) - adults: DM + malignancy
- juvenile: DM + ulcers
6. Anti-MDA-5 Melanoma differentiation- DM: not exactly not exactly 
-associated gene 5 (MDA5) - ulcers known known
- mild myositis
- arthritis
- ILD
7. Anti-NXP2 Nuclear matrix protein 2 DM: <5% 23-25%
(NXP2) - adults: severe DM + malignancy
- juvenile: DM + calcinosis
8. Anti-200/100 3-hydroxy-3-methylglutaryl- Statin induced NAM: <10% not exactly 
-coenzyme A reductase - in general rapid progress known
(HMGCR) - severe myositis
- severe cardiac involvement
- severe dysphagia
9. Anti-Mup44 Cytosolic 5'-nucleotidase 1A IBM 4% 
(cN1A) (in IBM: 33%)
(Abbreviations: ARS: amino-acyl-tRNA synthetase; ASS: anti-synthetase syndrome; cN1A: cytosolic 5’-nucleotidase 1A; DM:
dermatomyositis; HMGCR: 3-hydroxy-3-methyl-glutaryl-CoA reductase; IBM: inclusion body myositis; IIM: idiopathic inflammatory
myopathy; ILD: interstitial lung disease; MDA5: melanoma differentiation-associated gene 5; NAM: necrotizing autoimmune myopathy;
NXP2: nuclear matrix protein 2; PM: polymyositis; SAE: small ubiquitin-like modifier activating enzyme; SRP: signal recognition particle;
TIF1γ: transcriptional intermediary factor 1 gamma) 
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FIgurE 3. HAQ score of the six examined Hungarian patients with double MSA positivity
(Abbreviations: HAQ: health assessment questionnaire; MSA: myositis-specific autoantibody; SRP: signal recognition particle) 
remission, she does gymnastics regularly. She has mild
arthralgia, mild dysphonia and mild myalgia. Her MMT
scores during the last four investigations were 65/80
and 121/150; 62/80 and 116/150; 65/80 and 122/150;
63/80 and 117/150; respectively..
The most important results about these six patients
are summarized in Table II. CK level and HAQ score
can be followed in Figures 2 and 3.
dIscussIon And LItErAturE rEvIEw
MSAs are clearly a useful diagnostic tool. It can be fur-
ther argued that they are useful for identifying distinct
subsets. Autoantibodies - as shown - can be therefore
used as specific markers for myositis. 36% of patients
have MSA in their sera26, and the majority of patients
have only one MSA. Our study represents however a
few exceptions and is of great interest to physicians.
This cohort is of importance because there is very limi -
ted information about such cases in the literature. We
draw clinicians’ attention to our set of cases that were
diagnosed with double MSA positivity.
Koenig et al. reported that a significant proportion
of IIM patients are characterized by complex associa-
tions of autoantibodies. It is important that they did
not report about the coexistence of two or more MSAs,
only about the associations of MSAs and MAAs27.
Our literature review is summarised in Table III. At
first Gelpí et al.28 described the immunologic findings
of a patient whose serum showed two different anti-
bodies: anti-Jo-1 and anti-OJ. These are two of the eight
anti-ARS antibodies29; the anti-synthetase syndrome
(ASS) is characterized by myositis, interstitial lung
disea se (ILD), symmetrical non-erosive arthritis, Ray-
nauds’ phenomenon, fever and mechanic’s hands30. The
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patient with anti-Jo-1 and anti-OJ had prominent
arthritis, lung fibrosis and subclinical myositis as part
of the ASS. Five of our patients showed ARS positivity.
All anti-Jo-1 positive patients and the patient with anti-
-PL-12 had typical pulmonary fibrosis during disease
course. The exception was the patient with anti-PL-7
positivity who had no lung involvement.
Anti-SRP positivity correlates with severe and pro-
gressive necrotizing myositis (NAM), and poor prog-
nosis31,32. The case of Sugie et al.33 is of great impor-
tance in connection with our study; their patient is the
only one in the literature who had the same antibodies
as two of our patients: anti-Jo-1 and anti-SRP. The six-
ty-one year old man had DM, progressively worsening
of muscle weakness, pleural effusion and ILD. He died
of papillary adenocarcinoma of the stomach because it
was a cancer-associated myositis. Our first patient also
acquired pulmonary fibrosis and Raynaud’s phe-
nomenon, as part of the anti-Jo-1 positive PM. Anti-
-SRP positivity was also associated with the typical, pro-
gressively worsening myositis. Our second patient had
DM, muscle weakness and ILD; in contrast with the
cited case she had a monophasic disease and is in re-
mission. Malkan et al.34 also reported a combination of
NAM and ASS with the rare finding of two MSAs: anti-
-SRP and anti-PL-12. The patient needed more aggres-
sive immunotherapy but showed good improvement.
Our patient with anti-SRP and anti-PL-7 – as mentio -
ned above – is in contrast with these cases. She had
myalgia, proximal muscle weakness and arthralgia;
these are specific symptoms neither for anti-SRP nor
for anti-PL-7. Her normal CK levels are notable, be-
cause lower (but not normal) CK levels in patients with
anti-PL-7 positivity were observed by Marie et al35.
tAbLE III. rEsuLts oF PrEvIous studIEs And cAsE rEPorts About IIM PAtIEnts wIth doubLE MsA 
PosItIvIty
Patient 
diagnosis MSA ANA
Study (gender) positivity profile Clinical features Treatment Prognosis
Gelpí et al. PM anti-Jo-1 + ASS with arthritis, steroid good clinical response
(1996)28 (F) anti-OJ ILD, myositis azathioprine
Sugie et al. DM, CAM anti-Jo-1 progressive, muscle steroid 4 month after onset: 
(2012)33 (M) anti-SRP + weakness, pleural papillary 
effusion, ILD adenocarcinoma of 
stomach; gastrectomy; 
died of ILD and liver
metastases
Nakajima PM-RA anti-Jo-1 + polyarthritis, myositis, no data good
et al. overlap anti-PL-7 ILD
(2012)39 (M)
PM-RA anti-Jo-1 – polyarthritis, myositis, no data good
overlap anti-PL-7 ILD
(M)
PM-RA anti-PL-7 + PM-RA overlap no data good
overlap anti-SRP
(F)
Malkan NAM anti-PL-12 no data NAM steroid good improvement
et al. (F) anti-SRP ASS IVIG
(2015)34 azathioprine
cyclophosphamide
rituximab
ANA: antinuclear antibody; ASS: anti-synthetase syndrome; CAM: cancer-associated myositis; DM: dermatomyositis; F: female; 
IIM: idiopathic inflammatory myopathy; ILD: interstitial lung disease; IVIG: intravenous immunglobulin; M: male; MSA: myositis-specific
antibody; NAM: necrotizing autoimmune myopathy; PM: polymyositis; RA: rheumatoid arthritis; SRP: signal recognition particle
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Our cohort is the first that describes anti-Mi-2 posi -
tive patients having another MSA. Traditionally anti-
-Mi-2 is strongly associated with severe skin lesions but
good response to therapy36-38. Other studies said that
anti-Mi-2 can also be detected in PM26. Three of our six
patients with MSA coexistence had anti-Mi-2 positivi-
ty. The PM/DM ratio was 2:1. One female patient had
anti-Jo-1 positivity and PM. She had muscle symptoms
and pulmonary fibrosis but no skin involvement. The
male patient had anti-PL-12 positivity and DM. Accor -
ding to Marie et al.35 the presence of anti- PL12 au-
toantibody is markedly associated with early and se-
vere ILD and gastrointestinal complications. Our male
patient showed DM with heliotrope rash, erythema on
face, shawl-sign, V-sign – these are typical for anti-Mi-2
positive DM. He also had extremely high level of CK,
severe acute ILD, high fever, Raynaud’s phenomenon
and arthralgia – these are the classical signs of the ASS.
The second female patient was diagnosed with anti-
-SRP positivity and PM. She has a chronic form of PM
without skin symptoms and cardiovascular disease acti -
vity. In this case we could not diagnose the signs of anti-
-SRP or anti-Mi-2 positivity.
Nakajima et al.39 investigated twelve patients with
IIM-RA overlap. Two out of twelve patients were con-
currently positive for two different MSAs: anti-Jo-1 and
anti-PL-7 antibodies. Both of the patients in this study
were males with mild polyarthritis, mild myositis and
mild ILD. One out of twelve patients was positive for
anti-PL-7 and anti-SRP but not at the same time.
concLusIon
MSAs, which characterize certain forms of inflamma-
tory myopathy, are useful in the diagnosis and predic-
tion of prognosis in DM/PM. Sugie et al.33 alleged that
the coexistence of two MSAs leads to more severe
symptoms, interacting in a complex fashion, thus ex-
panding the clinical spectrum of IIM. Investigating six
patients with two MSAs in our Hungarian IIM popula-
tion we conclude the followings. It cannot be stated
that these associations all have a more serious course
or a more severe phenotype. Only one patient died of
an extreme severe form of myositis. We can state that
only two patients matched the characteristic features of
both antibodies; two patients fitted one antibody’s an-
ticipated symptoms; two patients had simple clinical
manifestations represented only with weakness and
myalgia. Based on these results and the literature re-
view the presence of more than one MSA is rather as-
sociated with a “mixture” of phenotypes. In clinical
practice the presence of one or two MSAs should be
carefully interpreted. The main message of this work is
that the physician has to evaluate these findings to-
gether with the clinical features. 
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